drugset / Trial / NCT02520453
Adjuvant Durvalumab for Esophageal Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Adjuvant Durvalumab vs Placebo for 1 year after complete resection of esophageal cancer following neoadjuvant CCRT.
Timeline
- Start
- 2016-02
- Primary completion
- 2021-06
- Completion
- 2021-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 20 mg/kg | Intravenous |